Hybrid Immunity Protects against Antibody Fading after SARS-CoV-2mRNA Vaccination in Kidney Transplant Recipients, Dialysis Patients, and Medical Personnel: 9 Months Data from the Prospective, Observational Dia-Vacc Study

Vaccines, Journal Year: 2024, Volume and Issue: 12(7), P. 801 - 801

Published: July 19, 2024

(1) Background: Compared to medical personnel, SARS-CoV-2mRNA vaccination-related positive immunity rates, levels, and preservation over time in dialysis kidney transplant patients are reduced. We hypothesized that COVID-19 pre-exposure influences both vaccination-dependent development a group-dependent manner. (2) Methods: evaluated 2- 9-month follow-up data our observational Dia-Vacc study, exploring specific cellular (interferon-γ release assay = IGRA) and/or humoral immune responses (IgA/IgG/RBD antibodies) after two vaccinations 2630 participants, including personnel (301-MP), (1841-DP), recipients (488-KTR). Study participants were also separated into (hybrid immunity) (n 407) versus negative 2223) groups. (3) Results: improved most rates KTR DP at 2 months but not MP, where reached almost 100% independent of hybrid immunity. In the COVID-19-negative patients’ faded between nine months, via percentage with an RBD antibody decrease >50%, was markedly group- (MP-17.8%, DP-52.2%, KTR-38.6%) vaccine type-dependent. contrast, all patient groups COVID-19, decreases >50% similarly rare (MP-4.3%, DP-7.2%, KTR-0%) still type-dependent, numerically reduced numbers mRNA-1273- BNT162b2mRNA-treated patients. Multivariable regression analysis changes by interval scale categorization confirmed as factor inhibiting strong Ab fading. MP T-cell DP, symptomatic (versus asymptomatic) identified reducing fading vaccination. (4) Conclusions: After mRNA vaccination, positivity well MP/DP/KTR, prior infection. compared asymptomatic disease particularly effective blocking

Language: Английский

Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study

Viruses, Journal Year: 2024, Volume and Issue: 16(8), P. 1345 - 1345

Published: Aug. 22, 2024

Background: COVID-19 continues to pose a threat immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 the benefit of prolonged half-life. Although approved for prevention, there is limited data on their effectiveness among heavily populations. Methods: We conducted prospective, observational study at Laiko General Hospital, Athens, Greece, from August December 2022 investigate efficacy TXG/CIL as form pre-exposure in patients. Data breakthrough infections were collected over six-month follow-up period. Results: Of 375 participants (mean age 61.3 ± 14.1 years; 59.7% male), 76 (20.3%) developed infections, an incidence 3.81 cases/100 patient months. Hospitalization was required 21 patients (5.6%), median stay 14 days. Seven deaths recorded, only one attributed COVID-19. Previous infection (OR 0.46, 95% CI 0.26–0.82) and hybrid immunity 0.52, 0.29–0.92) can protect new infection. Solid organ malignancy significantly increased risk severe outcomes those infected 7.4, 2.2–24.7, p = 0.001). Conclusions: provides effective Future strategies should focus developing mAb combinations address emerging variants vulnerable

Language: Английский

COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients

Vaccine, Journal Year: 2024, Volume and Issue: 44, P. 126544 - 126544

Published: Nov. 29, 2024

Language: Английский